Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
SAVA — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

16.7

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

-1.4

EPS This/Next Y

0.71

Price

2.37

Target Price

8

Analyst Recom

1

Performance Q

-25.39

Upside

N/A

Beta

-0.82

Ticker: SAVA



20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-09SAVA2.120.250.7335831
2026-03-10SAVA2.380.250.0236187
2026-03-11SAVA2.380.250.0236187
2026-03-12SAVA2.380.250.0236187
2026-03-13SAVA2.380.250.0236187
2026-03-17SAVA2.380.250.0236187
2026-03-18SAVA2.38N/AN/A0
2026-03-19SAVA2.38N/AN/A0
2026-03-20SAVA2.38N/AN/A0
2026-03-23SAVA2.38N/AN/A0
2026-03-24SAVA2.38N/AN/A0
2026-03-25SAVA2.38N/AN/A0
2026-03-26SAVA2.38N/AN/A0
2026-03-27SAVA2.38N/AN/A0
2026-03-30SAVA2.38N/AN/A0
2026-03-31SAVA2.38N/AN/A0
2026-04-01SAVA2.38N/AN/A0
2026-04-02SAVA2.38N/AN/A0
2026-04-06SAVA2.38N/AN/A0
2026-04-07SAVA2.38N/AN/A0
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1



3 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-09SAVA2.11- - -1.93
2026-03-10SAVA2.37- - -1.93
2026-03-11SAVA2.37- - -1.93
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
3 items Current Page1 of 1



2 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-09SAVA9.49-0.0816.70
2026-03-10SAVA9.49-0.0816.70
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2 items Current Page1 of 1

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

-0.3

Avg. EPS Est. Next Quarter

-0.31

Insider Transactions

9.49

Institutional Transactions

-0.08

Beta

-0.82

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

7

Growth Score

17

Sentiment Score

94

Actual DrawDown %

98.4

Max Drawdown 5-Year %

-99.1

Target Price

8

P/E

Forward P/E

PEG

P/S

P/B

1.41

P/Free Cash Flow

EPS

-2.2

Average EPS Est. Cur. Y​

-1.93

EPS Next Y. (Est.)

-1.22

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

2.5

Return on Equity vs Sector %

-157.8

Return on Equity vs Industry %

-141.7

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

No data found for SAVA
Cassava Sciences, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 30
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
SAVA

Latest News

—
Caricamento notizie per SAVA…
stock quote shares SAVA – Cassava Sciences, Inc. Stock Price stock today
news today SAVA – Cassava Sciences, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch SAVA – Cassava Sciences, Inc. yahoo finance google finance
stock history SAVA – Cassava Sciences, Inc. invest stock market
stock prices SAVA premarket after hours
ticker SAVA fair value insiders trading